Know about HPV+ oropharyngeal and anal cancer recurrence earlier and more accurately.
Don’t miss the opportunity to intervene early.
Within 5 years of treatment, cancer recurs for up to 1 in 4 HPV+ oropharyngeal cancer and 1 in 3 HPV+ anal cancer patients3,4,5
Up to one half of first recurrences for oropharyngeal are in a new part of the body (distant metastasis)6
HPV+ oropharyngeal and anal cancer recurrence can be detected over a year before symptoms appear with NavDx testing4,7
The NavDx test is the first and most clinically validated blood test that aids in the early detection of HPV-driven cancer
Detecting recurrence early, when disease burden is low, may improve a patient’s chances of long-term survivorship6,9,10
Know The Status.
Know your patient’s status more accurately with the NavDx® test, the most studied and clinically utilized test for detection of HPV+ oropharyngeal or anal cancer. This tumor-naive liquid biopsy analyzes a unique biomarker of tumors driven by HPV: tumor tissue modified viral (TTMV®)-HPV DNA.
Earlier detection of recurrent disease, helps ensure you do not miss the opportunity to deliver targeted treatments that can maximize patient benefit while minimizing morbidity.
Published studies show NavDx testing accurately and reliably predicted recurrence of oropharyngeal and anal cancer.4,8
For patients with HPV+ oropharyngeal cancer
≥ 95%
of people with one positive test had cancer recur (PPV)
≥ 98%
of people who routinely tested negative had no cancer recurrence (NPV)
For patients with HPV+ anal cancer
≥ 96%
of people with one positive test had cancer recur (PPV)
≥ 92.5%
of people who routinely tested negative had no cancer recurrence (NPV)
Industry-leading turnaround time. No need for baseline testing.
Unlike tumor-informed MRD tests, a baseline test is unnecessary. So you can test at any point in a patient’s cancer journey. HPV+ oropharyngeal or anal cancer recurrence monitoring is effective and efficient. Receive NavDx test results within seven business days from receipt of the sample at our lab from a simple blood draw, performed in-office or through our nationwide mobile phlebotomy access. The streamlined process is supported by our provider portal and responsive Patient Navigation Team.
Comprehensive resources and support
Learn how to incorporate NavDx testing
Review a sample test report
Explore case studies of NavDx testing in practice
Order a test
Want more details?
Do you have any questions about the NavDx test? We’re here to help. Fill out the form and a Naveris Product Development Representative will contact you.
1. Guo T, Kang SY, Cohen EEW. Current perspectives on recurrent HPV-mediated oropharyngeal cancer. Front Oncol. 2022;12. doi:10.3389/fonc.2022.966899
2. Temperley HC, Mac Curtain BM, O’Sullivan NJ, et al. Factors Influencing Outcomes and Survival in Anal Cancer. Curr Oncol. 2024;31(9):5151-5163. Published 2024 Sep 2. doi:10.3390/curroncol31090381
3. Chen AM, Harris JP, Gan M, et al. Posttreatment Surveillance Imaging After Radiation for Head and Neck Cancer. JAMA Netw Open. 2023;6(11):e2342825.
4. Kabarriti R, Lloyd S, Jabalee J, Del Vecchio Fitz C, Tao R, Slater T, Jacobs C, Inocencio S, Rutenberg M, Matthiesen C, et al. Evaluating Tumor Tissue Modified Viral (TTMV)-HPV DNA for the Early Detection of Anal Squamous Cell Carcinoma Recurrence. Cancers. 2025; 17(2):174. https://doi.org/10.3390/cancers17020174
5. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35. doi:10.1056/NEJMoa0912217
6. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial [published correction appears in Lancet. 2020 Mar 7;395(10226):784. doi: 10.1016/S0140-6736(20)30454-2.]. Lancet. 2019;393(10166):40-50. doi:10.1016/S0140-6736(18)32779-X
7. Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol. Apr 1 2020;38(10):1050-1058. doi:10.1200/JCO.19.02444.
10. Ferrandino RN, Chen S, Kappauf C, et al. Performance of liquid biopsy for diagnosis and surveillance of human papillomavirus–associated oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2023.1937.
8. Hanna GJ, Roof SA, Jabalee J, et al. Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance. Clin Cancer Res 2023
9. Ryuk JP, Choi G, Park JS, et al. Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection. Ann Surg Treat Res. 2014 Mar;86(3):143-151.
10. Ferrandino RN, Chen S, Kappauf C, et al. Performance of liquid biopsy for diagnosis and surveillance of human papillomavirus–associated oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2023.1937.
NavDx-1125-247
